SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Clinical trial NCT05642780 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05642780
- Sponsor
- Klus Pharma Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-17
- Primary completion
- 2027-11-30
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.